Table 1.
Participant demographics
| Measure | ASD (n = 13) | Neurotypicals (n = 15) | Test statistic |
|---|---|---|---|
| Age at visit 1 (years) | 30.6 ± 11.2 [20–50] | 28.5 ± 6.1 [21–40] | F(1, 26) = 0.389, p = .538 |
| ADI coma | 7.5 ± 5.0 | ||
| ADI repa | 4.0 ± 2.6 | ||
| ADOS com | 4.4 ± 3.3 | ||
| ADOS soc | 7.6 ± 4.1 | ||
| AQa | 29.1 ± 13.7 | ||
| FSIQ | 113.0 ± 18.1 | 125.3 ± 12.7 | F(1, 26) = 4.421, p = .045 |
| TV1–V2 (days) | 31.2 ± 17.9 | 28.1 ± 15.0 | F(1, 26) = 0.248, p = .623 |
| Mean motion (CBDV) | 0.015 ± 0.067 | 0.008 ± 0.043 | F(1, 26) = 0.100, p = .754 |
| Mean motion (PLC) | 0.014 ± 0.049 | 0.008 ± 0.050 | F(1, 26) = 0.097, p = .758 |
Demographics (mean ± standard deviation [range])) and test statistic of between-group comparison
ADI autism diagnostic interview (com, communication domain; rep, restricted and repetitive behaviours domain), ADOS autism diagnostic observation schedule (com, communication domain; soc, social domain), AQ autism quotient, CBDV cannabidivarin, FSIQ full-scale intelligence quotient, PLC placebo, TV1–V2, time between visits 1 and 2
an = 10